Cara Therapeutics names CMO
This article was originally published in Scrip
Cara Therapeutics, a biopharmaceutical company focused on developing medicines for pain and pruritus by selectively targeting kappa opioid receptors, has named Joseph Stauffer chief medical officer. Dr Stauffer will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies. He has previously worked at a number of specialty pharma companies including Ikaria and Alpharma.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.